Heterotopic ossification is a potentially severe pathology in which ectopic bone forms within muscles and connective tissues and near blood vessels or nerves. More than 10% of patients who undergo invasive surgery can develop heterotopic ossification [1] [2] [3] , and 65% of seriously wounded soldiers develop the disease as well 4 , causing chronic pain, problems with fitting prostheses, deep venous thrombosis, limited motion and other complications. Although the pathogenesis of this condition remains unclear, it is generally agreed that the inciting events-trauma, surgery, deep burns or protracted immobilization-induce local inflammation 5, 6 . This is followed by the recruitment of skeletal progenitor cells that differentiate into chondrocytes, undergo hypertrophy and are replaced by endochondral bone. Individuals with the rare congenital condition fibrodysplasia ossificans progressiva (FOP) develop extensive heterotopic ossification that is also induced by trauma and inflammation 7 , is aggressive and often fatal and is propelled by an activating mutation in the BMP type I receptor ALK2 R206H (ref. 8). Given the etiology of heterotopic ossification, current therapeutic treatments aim to target different pathogenic steps, but they have had varied success and are far from ideal 9, 10 .
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A recent study tested a selective inhibitor of BMP type I receptor kinases in transgenic mice 11 that express a strong, constitutively active ALK2 Q207D mutant 12 and found some inhibition of muscleassociated heterotopic ossification 13 . Using a standard mouse model of subcutaneous heterotopic ossification, we tested a selective agonist for the nuclear RAR-α 14 . The rationale was based on the fact that retinoid signaling is a strong inhibitor of chondrogenesis 15 and that unliganded RAR transcriptional repressor activity-possibly involving RAR-α-is needed for chondrogenic differentiation 16, 17 . The RAR-α agonist did inhibit heterotopic ossification, but not completely. To further explore the idea of a retinoid agonist-based therapy for heterotopic ossification, we considered the fact that another RAR family member with distinct characteristics 18 , RAR-γ, is expressed in chondrogenic cells 17 and chondrocytes 19 where it also operates as an unliganded transcriptional repressor 20 . Hence, a therapy for heterotopic ossification that was based on RAR-γ agonists could be more effective because it would target both chondrogenic cells and chondrocytes. The data presented here support this possibility.
RESULTS

RAR-g agonists block chondrogenesis
To test whether RAR-γ agonists inhibit chondrogenesis, we treated micromass cultures of mouse embryo limb mesenchymal cells isolated on embryonic day (E) 11.5 with the synthetic selective RAR-γ agonist NRX204647 (refs. 20,21) . For comparison, we treated companion cultures with all-trans-retinoic acid, the active natural vitamin A derivative that is a pan-agonist of the RAR family (RAR-α, RAR-β and RAR-γ) and is well known for its antichondrogenic action 15 . Whereas numerous Alcian blue-positive cartilaginous nodules formed in control cultures (Fig. 1a) , few if any formed in cultures treated with NRX204647; inhibition was greater than that elicited by comparable doses of all-trans-retinoic acid (Fig. 1a) .
To test the relevance of RAR-γ in regulating chondrogenesis, we prepared micromass cultures with limb mesenchymal cells from E11.5 RAR-γ-null embryos that still expressed RAR-α and RAR-β (ref. 20) . Treatment with all-trans-retinoic acid failed to inhibit chondrogenesis in these RAR-γ-null cultures (Fig. 1b) . To verify the apparent centrality of RAR-γ, we prepared micromass cultures with limb mesenchymal cells isolated from E11.5 double RAR-α-null, RAR-β-null embryos (which still expressed RAR-γ) and treated them with all-trans-retinoic acid (for analysis of conditional gene deletion and genotyping, see Supplementary Fig. 1 ). Chondrogenesis was fully suppressed by alltrans-retinoic acid in these double-mutant cultures as well as in companion wild-type cultures (Fig. 1c) . Thus, RAR-γ agonists can block chondrogenic differentiation, and RAR-γ seems to exert a strong role in the control of chondrogenesis.
RAR-g agonists block trauma-induced heterotopic ossification
To determine whether RAR-γ agonists inhibit heterotopic ossification, we used a standard mouse model that combines local trauma and implantation of a skeletogenic factor 22 . In such models 14 , progenitor cells are recruited to the injured site and form cartilage by day 5 or 6; cartilage undergoes hypertrophy and is replaced by endochondral bone by days 10-14. We created a small microsurgical pouch in the calf muscles of 2-month-old female mice and inserted a collagen sponge containing 1 µg of recombinant bone morphogenetic protein-2 (BMP-2) as a skeletogenic factor. Starting on day 1, mice received daily doses of NRX204647 (1.2 mg per kg body weight per day), all-trans-retinoic acid (12 mg per kg body weight per day) or corn oil (vehicle control) by gavage for 12-14 d. Large ectopic mineralized tissue masses formed in vehicle-treated mice at the operated site near the tibia and fibula by day 14 (Fig. 1d) , but formation of such tissues was markedly reduced in mice treated with all-trans-retinoic acid and essentially prevented in mice treated with the selective RAR-γ agonist (Fig. 1d) . Staining with Masson's trichrome and alcian blue showed that ectopic masses in control mice contained abundant cartilage, endochondral bone and marrow (Fig. 1d ) and proliferative cells (Supplementary Fig. 2 ), but all these tissues were diminished in mice treated with all-transretinoic acid and were essentially absent in mice treated with the selective RAR-γ agonist (Fig. 1d) ; the number of proliferative cells was also lower (Supplementary Fig. 2 ). Consistent with these results, amounts of the bone markers osteocalcin and tartrate-resistant alkaline phosphatase (TRAP) were prominent in control ectopic tissues, were clearly reduced in mice treated with all-trans-retinoic acid and were undetectable in mice treated with the selective RAR-γ agonist (Fig. 1d) . We obtained identical results in a model of subcutaneous heterotopic ossification (Fig. 1e) used previously 14 .
Because the drugs are given systemically, they could have unwanted side effects. However, we found no obvious changes in food intake and blood chemistry (Supplementary Fig. 3 ) or in trabecular npg bone density ( Supplementary Fig. 4 ). The mice that received the highest does of all-trans-retinoic acid (12 mg per kg body weight per day) showed skin redness and loss of some whiskers, and those that received the highest dose of NRX204647 (1.2 mg per kg body weight per day) showed a transient delay in long-bone fracture repair ( Supplementary Fig. 3 ).
Drug class effect of RAR-g agonists
Synthetic RAR-γ agonists differ in their chemical and physical characteristics, backbone structure and effectiveness 21, [23] [24] [25] . We compared the ability of NRX204647 to inhibit heterotopic ossification with that of the RAR-γ agonists CD1530 and R667 (Fig. 2a) to determine whether inhibition of heterotopic ossification is a drug class effect. We implanted 2-month-old mice with 1 µg recombinant BMP-2 (rBMP-2) in 250 µl Matrigel subcutaneously to induce heterotopic ossification 14 and administered the indicated daily doses of NRX204647, CD1530 (ref. 26) or R667 (ref. 27) by gavage. For comparison, companion groups of mice received daily doses of: corn oil (vehicle control), retinol (the largely inert precursor of natural active retinoids) 28 , alltrans-retinoic acid, 13-cis-retinoic acid, which has been tested for the prevention of heterotopic ossification in patients with FOP 29 , or the RAR-α agonist NRX195183, which has previously been tested in a mouse model of heterotopic ossification 14 . Large subcutaneous ectopic masses of vascularized and mineralized tissues formed in control mice, but their formation was dose-dependently inhibited by each RAR-γ agonist tested, as indicated by soft X-ray, histology and microcomputed tomography (µCT)-based quantification of bone volume/total volume (BV/TV) ratios (Fig. 2b,c) . Because all of the RAR-γ agonists were effective, we used them interchangeably in subsequent experiments. In line with the above data and previous work, the pan-agonist all-trans-retinoic acid and the RAR-α agonist NRX185183 also inhibited heterotopic ossification, but their effectiveness was partial and required high doses 30 (Fig. 2b) . Retinol had no effect, but 13-cis-retinoic acid had a slight and consistent stimulatory effect (Fig. 2b) , which might account for the occurrence of flare ups in certain patients with FOP that were treated with it 29 .
To verify the specificity of RAR-γ agonist action, we induced subcutaneous heterotopic ossification in RAR-γ-null mice, mice heterozygous for the gene encoding RAR-γ and wild-type mice and treated them with CD1530 or NRX204647 for 12-14 d. The agonists blocked heterotopic ossification in wild-type and heterozygous mice as expected, but not in RAR-γ-null mice (Fig. 2d) .
To determine whether heterotopic ossification would restart after drug treatment ended (a phenomenon referred to 'rebound effect'), we induced subcutaneous heterotopic ossification and treated the mice with CD1530 or corn oil (control) for 10 d. A few control and treated mice were killed at that point, and the remaining mice were withdrawn from drug treatment and examined over time. Ectopic tissues grew in control mice, but only minimally in mice treated with CD1530, indicating that there was no rebound npg effect (Fig. 2e) . We tested the RAR-α agonist NRX195183 and observed a rebound effect in this case (Fig. 2e) . Last, we tested whether the RAR-γ agonists would be effective against heterotopic ossification even if treatment did not start immediately, providing insights into the 'window of opportunity' . We started treatment with CD1530 or corn oil on day 6 (corresponding to the chondrogenic phase of heterotopic ossification) and continued it for 6-8 d. The RAR-γ agonist was still able to block heterotopic ossification (Fig. 2f) . However, when treatment was delayed until day 12 (corresponding to the osteogenic phase), the RAR-γ agonist had little or no effect (Supplementary Fig. 5) . Together, the data indicate that the agonists block heterotopic ossification by preventing chondrogenic cell differentiation and cartilage formation but have minimal effects once bone has formed.
Prevention of heterotopic ossification in ALK2 Q207D mice Congenital heterotopic ossification in individuals with FOP is driven by the ALK2 R206H mutant protein 8 , which has mild basal constitutive activity but becomes hyperactive upon ligand binding 31 . To determine whether RAR-γ agonists could be effective against congenital heterotopic ossification, we prepared an expression vector encoding the constitutively active ALK2 Q207D mutant, which induces chondrogenesis and endochondral ossification in chicks 12 , and expressed it in ATDC5 chondrogenic cells along with the BMP signaling reporter plasmid Id1-luc 32 . We treated the cells with different doses of CD1530 and measured luciferase activity after 24 h. Reporter activity increased markedly in ALK2 Q207D-expressing cells compared to empty vector control cells, but this increase was inhibited by CD1530 treatment (Fig. 3a) .
To test the effectiveness of CD1530 in vivo, we used conditional ALK2 Q207D-transgenic mice in which the effectiveness of a BMP type I receptor kinase inhibitor against FOP-like heterotopic ossification has been tested 13 . We injected mice intramuscularly with adenoCre in a hind limb and then treated them with CD1530 or vehicle. Massive heterotopic ossification developed in vehicle-treated mice, but heterotopic ossification was essentially absent in CD1530-treated mice (Fig. 3b,c) . To verify these data, we injected mice with alizarin complexon before they were killed. Tissue from mice treated with vehicle showed abundant alizarin complexon staining, but there was no obvious alizarin complexon-positive tissue in CD1530-treated mice (Fig. 3d) .
RAR-g agonists reduce BMP signaling
To clarify the mechanisms by which the RAR-γ agonists inhibit heterotopic ossification, we co-transfected ADTC5 cell cultures with the Id1-1uc reporter plasmid and treated them with various CD1530 concentrations (0-100 nM) in the absence or presence of exogenous rBMP-2 (100 ng ml −1 ) for 24 h. Luciferase activity was stimulated more than tenfold by rBMP-2 treatment, but this increase was counteracted by simultaneous treatment with CD1530 (Fig. 4a) or NRX204647 (data not shown). BMPs transmit signals by transient phosphorylation of Smad1, Smad5 and Smad8 proteins (p-Smads) (ref. 33 ). Immunoblot analysis with antibodies to p-Smad1, 5 and 8 showed that in control cells Smad phosphorylation was already strong after 30 min of BMP-2 treatment (100 ng ml −1 ), peaked at 1 h and returned to basal levels by 3 h (Fig. 4b) . Concurrent treatment with CD1530 reduced the amounts of p-Smad proteins by more than 80%, as estimated by imaging quantification and normalization to α-tubulin amounts (Fig. 4b) . Treatment with CD1530 could have provoked such a drop in p-Smad abundance by affecting mechanisms involved in signal transduction and Smad phosphorylation or by reducing the overall steady-state levels of Smad proteins. To test the latter possibility, we processed identical immunoblots with antibodies to Smad1. There was a marked reduction in overall Smad1 abundance in CD1530-treated cells, whereas these levels remained essentially unchanged in companion control cells (Fig. 4b) . The decreases in Smad1 were appreciable by immunofluorescence staining (Fig. 4c) . In control cells, Smad1 was largely if not exclusively confined to the cytoplasm, but as expected it relocated to the nucleus upon treatment with rBMP-2 (Fig. 4c) . In cells treated with CD1530 for 24 h (in the absence or presence of rBMP-2), there was little if any Smad1 in the cytoplasm or nucleus (Fig. 4c) . In addition, there were similar decreases in the overall amounts of Smad5 and regulatory Smad4 in CD1530-treated cells (Fig. 4d) .
We wondered whether the reductions in Smad protein resulted from shunting toward degradation 34 npg to the expected drop in Smad1, this response was mitigated by treatment with either proteasome inhibitor (Fig. 4e ).
An RAR-g agonist alters cell differentiation potential
The marked reduction in steady-state amounts of Smad1, Smad4 and Smad5 caused by RAR-γ agonists suggested that the progenitor cells could have lost their lineage assignment and skeletogenic potentials.
To test this possibility, we treated ADTC5 cells in monolayer with 1 µM CD1530 or vehicle for 2 d. Control and CD1530-treated cells were then detached, rinsed, reseeded in multiwell cultures, grown in the absence or presence of 100 ng ml −1 rBMP-2 for an additional 7 d (without further CD1530 treatment) and assessed for chondrogenic differentiation. As expected, control cells underwent differentiation upon rBMP-2 treatment and stained strongly with alcian blue (a measure of chondrocyte differentiation and cartilage matrix accumulation) and for alkaline phosphatase activity (a measure of chondrocyte maturation; Fig. 5a,b) . However, CD1530-pretreated cells did not (Fig. 5a,b) . To verify these data, we repeated the npg experiments with bone marrow-derived mesenchymal stem cells (MSCs) isolated from a reporter mouse line 35 . Whereas control cells treated with rBMP-2 underwent differentiation and stained strongly with alizarin red (Fig. 5c) and for alkaline phosphatase (data not shown), CD1530-pretreated cells did not (Fig. 5c) . In ADTC5 cells (Fig. 4d) , CD1530 treatment lowered steady-state levels of Smad proteins and counteracted the response to rBMP-2, as indicated by Id1-luc activity (Fig. 5d,e) .
To test whether a similar loss of skeletogenic potential occurred in vivo, the bone marrow-derived MSCs were first grown for 2-3 d in monolayer in the presence or absence of 100 nM CD1530. The cells were then detached, mixed with Matrigel-rBMP-2 and implanted subcutaneously in nude mice. Because the cells express GFP, they were readily distinguishable from host cells. Control cells produced conspicuous masses of endochondral bone by 2 weeks that were obvious by µCT and histology and contained numerous GFP-and osteocalcin-positive cells (Fig. 5f) . However, the CD1530-pretreated cells largely did not produce ectopic bone, although they were present in large numbers, as revealed by their strong GFP signal (Fig. 5f) . Bone volume/total volume quantification showed that the reduction in ectopic bone formation was more than 95%.
DISCUSSION
Here we have shown that RAR-γ agonists are potent inhibitors of intramuscular and subcutaneous heterotopic ossification and can even mitigate ectopic skeletal tissue formation induced by the constitutively active ALK2 Q207D mutation. The inhibition of heterotopic ossification seems to be largely irreversible, because there were minimal rebound effects when we stopped drug treatment; in addition, the drugs seem to have minimal side effects. As chondrogenesis normally requires a drop in retinoid signaling and a concurrent upregulation of pro-chondrogenic pathways including BMP signaling 15, 36 , it is likely that the RAR-γ agonists inhibit chondrogenesis and heterotopic ossification by maintaining active retinoid signaling and liganded RAR activity while dampening BMP signaling. Our data also indicate that the latter effect involves not only inhibition of Smad phosphorylation, but also a marked proteasome-mediated drop in overall Smad abundance and a concurrent reprogramming of the progenitor cells into a nonskeletogenic lineage. A recent study of ALK2 Q207D-transgenic mice found no substantial decrease in overall Smad levels after treatment of skeletogenic cells with BMP type I receptor kinase inhibitors 13 , indicating that the RAR-γ agonists use distinct and broader modes of action and might therefore be more potent. Liganded RAR-γ has been shown to interact directly with Smad proteins and to inhibit their function 37 , and liganded RAR-γ increases Wnt-β-catenin signaling 38 . Because Wnt-β-catenin signaling is a potent inhibitor of chondrogenesis 39, 40 , it follows that the RAR-γ agonists probably block chondrogenesis and heterotopic ossification by reciprocally increasing Wnt-β-catenin signaling while decreasing signaling through BMP and possibly other pathways 41 . In summary, the RAR-γ agonists have the biological properties needed to interfere with the specific processes and mechanisms that are needed for the initiation and progression of heterotopic ossification and might therefore represent effective remedies, probably the most effective reported so far, for this condition and related ectopic ossification conditions 42, 43 .
Several notes of caution must be considered before retinoid agonists can be tested in humans. More in-depth studies need to be carried out to exclude side effects. The transient delay in fracture repair seen in mice treated with RAR-γ agonists could be of concern for patients such as wounded soldiers who may have severe bone fractures. However, these fractures are often subjected to stabilization and traction before healing and as inflammation subsides 44 , which could provide a window of opportunity for retinoid treatment and the prevention of heterotopic ossification. The agonists could also have negative effects on the growth plate in developing skeletal elements, either directly or through excess Wnt-β-catenin signaling. If so, this would be a concern for long-term treatment of children with FOP. However, because the RAR-γ agonists act rapidly and at least in part by diverting the skeletogenic potentials of progenitor cells, it is possible that treatment could be short or intermittent, which would allow the growth plate to recover in between treatments. Lastly, although all the RAR-γ agonists tested here are very effective, we need to identify the leading candidate for clinical development. Given its particularly strong activity 20 , NRX204647 should be at the top of the list, but this drug has not been tested in humans. In contrast, R667 (also known as Palovarotene) is already in a phase 2 clinical trial for emphysema 27 and could therefore move toward a clinical trial for heterotopic ossification in an efficient manner.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
